Cargando…

Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer

Immune‐related pneumonitis is an uncommon but potentially fatal immune‐related adverse event in advanced non–small cell lung cancer (NSCLC) patients during treatment with anti‐programmed cell death 1 (PD‐1) and programmed cell death‐ligand 1 (PD‐L1). Underlying emphysema, interstitial lung disease (...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yuxin, Shao, Chi, Li, Shan, Xu, Yan, Xu, Kai, Zhang, Ying, Huang, Hui, Wang, Mengzhao, Xu, Zuojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754394/
https://www.ncbi.nlm.nih.gov/pubmed/32757454
http://dx.doi.org/10.1111/ajco.13380
_version_ 1783626184992489472
author Sun, Yuxin
Shao, Chi
Li, Shan
Xu, Yan
Xu, Kai
Zhang, Ying
Huang, Hui
Wang, Mengzhao
Xu, Zuojun
author_facet Sun, Yuxin
Shao, Chi
Li, Shan
Xu, Yan
Xu, Kai
Zhang, Ying
Huang, Hui
Wang, Mengzhao
Xu, Zuojun
author_sort Sun, Yuxin
collection PubMed
description Immune‐related pneumonitis is an uncommon but potentially fatal immune‐related adverse event in advanced non–small cell lung cancer (NSCLC) patients during treatment with anti‐programmed cell death 1 (PD‐1) and programmed cell death‐ligand 1 (PD‐L1). Underlying emphysema, interstitial lung disease (ILD), and previous radiation therapy for lung cancer might be factors precipitating immune‐related pneumonitis. The incidence of immune‐related pneumonitis is reported to be higher in those treated with PD‐1 inhibitors than in those treated with anti‐PD‐L1 inhibitors. Early detection and diagnosis and appropriate management according to the severity are critical to improving the prognosis. The first‐line physicians, including the primary responsible oncologists, family doctors, emergency physicians and NSCLC patients should be trained to identify and report symptoms of immune‐related pneumonitis as early as possible. Multidisciplinary treatment teams involving clinicians (including ILD specialists and lung cancer specialists), radiologists and pathologists are recommended for the treatment of immune‐related pneumonitis.
format Online
Article
Text
id pubmed-7754394
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77543942020-12-23 Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer Sun, Yuxin Shao, Chi Li, Shan Xu, Yan Xu, Kai Zhang, Ying Huang, Hui Wang, Mengzhao Xu, Zuojun Asia Pac J Clin Oncol Reviews Immune‐related pneumonitis is an uncommon but potentially fatal immune‐related adverse event in advanced non–small cell lung cancer (NSCLC) patients during treatment with anti‐programmed cell death 1 (PD‐1) and programmed cell death‐ligand 1 (PD‐L1). Underlying emphysema, interstitial lung disease (ILD), and previous radiation therapy for lung cancer might be factors precipitating immune‐related pneumonitis. The incidence of immune‐related pneumonitis is reported to be higher in those treated with PD‐1 inhibitors than in those treated with anti‐PD‐L1 inhibitors. Early detection and diagnosis and appropriate management according to the severity are critical to improving the prognosis. The first‐line physicians, including the primary responsible oncologists, family doctors, emergency physicians and NSCLC patients should be trained to identify and report symptoms of immune‐related pneumonitis as early as possible. Multidisciplinary treatment teams involving clinicians (including ILD specialists and lung cancer specialists), radiologists and pathologists are recommended for the treatment of immune‐related pneumonitis. John Wiley and Sons Inc. 2020-08-05 2020-12 /pmc/articles/PMC7754394/ /pubmed/32757454 http://dx.doi.org/10.1111/ajco.13380 Text en © 2020 The Authors. Asia‐Pacific Journal of Clinical Oncology published by John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Reviews
Sun, Yuxin
Shao, Chi
Li, Shan
Xu, Yan
Xu, Kai
Zhang, Ying
Huang, Hui
Wang, Mengzhao
Xu, Zuojun
Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
title Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
title_full Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
title_fullStr Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
title_full_unstemmed Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
title_short Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
title_sort programmed cell death 1 (pd‐1)/pd‐ligand 1(pd‐l1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754394/
https://www.ncbi.nlm.nih.gov/pubmed/32757454
http://dx.doi.org/10.1111/ajco.13380
work_keys_str_mv AT sunyuxin programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer
AT shaochi programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer
AT lishan programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer
AT xuyan programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer
AT xukai programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer
AT zhangying programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer
AT huanghui programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer
AT wangmengzhao programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer
AT xuzuojun programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer